New drug IGT-303 tested for safety in kidney disease patients
NCT ID NCT07231679
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of a new drug called IGT-303 in healthy volunteers and people with chronic kidney disease (CKD). About 94 participants will receive either the drug or a placebo, given as a shot under the skin or into a vein. Researchers will monitor for side effects to see if IGT-303 is safe enough for further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Momentum Clinical Research
RECRUITINGWaikanae Beach, Kapiti Coast, 5036, New Zealand
-
Nucleus Network
RECRUITINGHerston, Brisbane, 4006, Australia
-
Pacific Clinical Research Network
RECRUITINGTakapuna, Auckland, 0622, New Zealand
-
University of Sunshine Coast-Morayfield
RECRUITINGMorayfield, Queensland, 4506, Australia
-
University of the Sunshine Coast Clinical Trials-Southbank
RECRUITINGMorayfield, Queensland, 4506, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a new pill quiet chronic pain? early trial puts it to the test
- Could your gut bacteria hold the key to protecting your kidneys?
- Brain waves under pressure: can light uncover the signature of mental work?